Pricing Log in Create free account
Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.68 2.06 +5.63%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Roivant Sciences Ltd. (ROIV) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 21, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 16, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Sep 8, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 28, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 27, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 17 added · 32 removed · 23 modified
P2I1A: 55 added 		Share dilution
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Mar 31, 2026 1: 58 added · 54 removed · 117 modified
1A: 62 added · 25 removed · 211 modified
7: 14 added · 15 removed · 37 modified
8-K May 20, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 2, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K/A Mar 3, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Mar 3, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 3, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025
8-K Feb 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 11, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 17, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 10, 2025 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Sep 3, 2025 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Mar 31, 2025
8-K May 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Dec 31, 2024
8-K Feb 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 13, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 13, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.